n Cardiovascular Journal of South Africa - Tenecteplase extends SA range of fibrinolytics : drug trends in cardiology




Extracted from text ... Tenecteplase is a triple combination mutant variant of alteplase with a high fibrin specificity and resistance to plasminogen activator inhibitor-1. The reduced rate of systemic clearance of the drug relative to alteplase allows tenecteplase to be given by rapid bolus injection to patients with acute myocardial infarction (AMI) with ST segment elevation. The efficacy of tenecteplase in AMI has been demonstrated in a phase I dose-ranging trial [Thrombolysis in Myocardial Infarction (TIMI) 10A], a non-blind phase II comparison with alteplase (TIMI 10B), and a randomised double-blind phase III comparison with alteplase in 16 949 patients ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error